Immuron Ltd
Business
Immuron Limited is an Australian biopharmaceutical company developing and commercializing orally delivered polyclonal antibodies derived from hyperimmune bovine colostrum to treat infectious and inflammatory diseases. The company markets Travelan® (for travelers' diarrhea prevention) and Protectyn® (immune supplement) primarily in Australia, Canada, and the United States. Immuron has two lead clinical-stage candidates—one targeting enterotoxigenic E. coli and travelers' diarrhea, the other targeting recurrent Clostridioides difficile infections—and collaborates with the U.S. Department of Defense on multiple anti-infective programs.
Summary from 20-F filed 2025-09-25
Financials
Latest annual snapshot (FY2025, period end 2025-06-30). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-5.22M |
| Total assets | $10.13M |
| Total liabilities | $2.06M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Immuron Ltd's CIK number?
Immuron Ltd's SEC CIK number is 0001660046 (1660046). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Immuron Ltd's SEC filings?
All of Immuron Ltd's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.